Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.59 |
| ▸ | GLS | O94925 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
| ▸ | PLK1 | P53350 | 1/20 | 0.49 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29440893 | 1.00 | HDAC3 (0.59) | HDAC3GLSNPC1POLBMAPT | |
| SCHEMBL1162253 | 0.87 | TP53 (0.60) | HDAC3MEN1KMT2ARAB9AHTT | |
| SCHEMBL24814483 | 0.85 | HDAC3 (0.58) | HDAC3GLSNPC1POLBMAPT | |
| SCHEMBL5340760 | 0.85 | HDAC3 (0.60) | HDAC3GLSNPC1POLBMAPT | |
| SCHEMBL31269838 | 0.85 | HDAC3 (0.60) | HDAC3GLSNPC1POLBMAPT | |
| SCHEMBL3584548 | 0.84 | DAO (0.52) | HDAC3GLSNPC1POLBMAPT | |
| SCHEMBL30244780 | 0.84 | DAO (0.52) | HDAC3GLSNPC1POLBMAPT | |
| SCHEMBL25139422 | 0.83 | HDAC3 (0.55) | HDAC3GLSNPC1POLBMAPT | |
| SCHEMBL359850 | 0.81 | ALOX15 (0.58) | HDAC3GLSNPC1POLBMAPT | |
| SCHEMBL25139421 | 0.81 | HDAC3 (0.54) | HDAC3GLSNPC1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119556538-A | Alkaline stripping liquid for silicon-based surface composite film and stripping method thereof | 湖北兴福电子材料股份有限公司 | 2025-03-04 | — | — | CN | claimed |
| CN-116003449-B | Synthesis method of tetrahydroquinoline compound with C-B bond | 广东以色列理工学院 | 2025-02-28 | — | — | CN | claimed |
| CN-118772552-B | Anti-aging PVC material | 揭阳市正信鞋业有限公司 | 2025-02-11 | — | — | CN | claimed |
| CN-118772552-A | Anti-aging PVC material | 揭阳市正信鞋业有限公司 | 2024-10-15 | — | — | CN | claimed |
| CN-118725580-A | Polymer-based waterproof insulating material and preparation method thereof | 深圳市高科塑化有限公司 | 2024-10-01 | — | — | CN | claimed |
| CN-111548546-A | Ultraviolet absorbent for anti-aging of polyethylene plastic products and preparation method thereof | 李道宏 | 2020-08-18 | — | — | CN | claimed |
| US-20260144743-A1 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-05-28 | — | — | US | disclosed |
| EP-4702033-A1 | DESMURAMYLPEPTIDE DIACIDS AS NOD2 AGONISTS AND USE THEREOF | Imhotex Limited (GB) | 2026-03-04 | — | — | EP | disclosed |
| EP-4699655-A2 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-02-25 | — | — | EP | disclosed |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | SERVIER LAB (FR) | 2026-01-01 | — | — | US | disclosed |
| US-12377105-B2 | Compounds | TMEM16A LIMITED (GB) | 2025-08-05 | — | — | US | disclosed |
| EP-4551566-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2025-05-14 | — | — | EP | disclosed |
| CN-119661553-A | Brucea javanica kurol quinoline derivative and preparation method and application thereof | 中国人民解放军西部战区总医院 | 2025-03-21 | — | — | CN | disclosed |
| US-20020119963-A1 | Imidazole derivatives | PFIZER PRODUCTS INC. | 2002-08-29 | — | — | US | disclosed |
| EP-1220852-A1 | SUBSTITUTED DIAZEPANS | Novartis AG (CH) | 2002-07-10 | — | — | EP | disclosed |
| US-6399599-B1 | ANTIINFLAMMATOY AGENTS; AUTOIMMUNE DISEASE | NOVARTIS AG (CH) | 2002-06-04 | — | — | US | disclosed |
| WO-2002010141-A1 | IMIDAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-02-07 | — | — | WO | disclosed |
| WO-2001027102-A1 | SUBSTITUTED DIAZEPANES | NOVARTIS AG (CH) | 2001-04-19 | — | — | WO | disclosed |
| US-5288749-A | Treating central nervous system or cardiovascular disorders | ABBOTT LABORATORIES (US) | 1994-02-22 | — | — | US | disclosed |
| WO-1993012754-A2 | TERTIARY AND SECONDARY AMINES AS ALPHA-2 ANTAGONISTS AND SEROTONIN UPTAKE INHIBITORS | ABBOTT LABORATORIES (US) | 1993-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144743-A1 | COMPOUNDS | CACNA1E, TMEM109, CACNA1C | HDAC3 878/4885GLS 648/4885NPC1 184/4885 |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BCL2A1, BAX | HDAC3 142/4885GLS 160/4885NPC1 625/4885 |
| US-20020119963-A1 | Imidazole derivatives | CDK1, CDK3, CDK2 | HDAC3 155/4885GLS 411/4885NPC1 4768/4885 |
| US-12377105-B2 | Compounds | CACNA1E, TMEM109, CACNA1A | HDAC3 1000/4885GLS 450/4885NPC1 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.